Inhaled triple therapy in chronic obstructive pulmonary disease

Brian Lipworth (Lead / Corresponding author), Chris Rui Wen Kuo, Sunny Jabbal

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)1112-1113
Number of pages2
JournalThe Lancet
Volume392
Issue number10153
Early online date27 Sep 2018
DOIs
Publication statusPublished - 29 Sep 2018

Cite this

@article{a8bde8451db94d0f8e7ea2acafb90eef,
title = "Inhaled triple therapy in chronic obstructive pulmonary disease",
author = "Brian Lipworth and Kuo, {Chris Rui Wen} and Sunny Jabbal",
note = "MM reports personal fees from Boehringer Ingelheim, GlaxoSmithKline, and Novartis. POG reports personal fees from AstraZeneca and personal fees and non-financial support from ALK-Abello, Boehringer Ingelheim, Chiesi, and Novartis. NM reports personal fees from Merck, Pfizer, IPSEN, MSD France, Servier, Novartis, and Oxon; and grants from Pierre Fabre, Biogen, Novartis, J&J, Vifor Pharma, Merck-Serono, Sanofi, Bayer, Lundbeck, Merck & Co, Allergan, AstraZeneca, BMS, J&J, Stallergene, and Boehringer Ingelheim, outside the submitted work",
year = "2018",
month = "9",
day = "29",
doi = "10.1016/S0140-6736(18)31795-1",
language = "English",
volume = "392",
pages = "1112--1113",
journal = "Lancet",
issn = "0140-6736",
publisher = "ELSEVIER SCIENCE INC",
number = "10153",

}

Inhaled triple therapy in chronic obstructive pulmonary disease. / Lipworth, Brian (Lead / Corresponding author); Kuo, Chris Rui Wen; Jabbal, Sunny.

In: The Lancet, Vol. 392, No. 10153, 29.09.2018, p. 1112-1113.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Inhaled triple therapy in chronic obstructive pulmonary disease

AU - Lipworth, Brian

AU - Kuo, Chris Rui Wen

AU - Jabbal, Sunny

N1 - MM reports personal fees from Boehringer Ingelheim, GlaxoSmithKline, and Novartis. POG reports personal fees from AstraZeneca and personal fees and non-financial support from ALK-Abello, Boehringer Ingelheim, Chiesi, and Novartis. NM reports personal fees from Merck, Pfizer, IPSEN, MSD France, Servier, Novartis, and Oxon; and grants from Pierre Fabre, Biogen, Novartis, J&J, Vifor Pharma, Merck-Serono, Sanofi, Bayer, Lundbeck, Merck & Co, Allergan, AstraZeneca, BMS, J&J, Stallergene, and Boehringer Ingelheim, outside the submitted work

PY - 2018/9/29

Y1 - 2018/9/29

UR - http://www.scopus.com/inward/record.url?scp=85053844412&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(18)31795-1

DO - 10.1016/S0140-6736(18)31795-1

M3 - Letter

AN - SCOPUS:85053844412

VL - 392

SP - 1112

EP - 1113

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 10153

ER -